First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

• 主要な著者: Hong Zhang (著者), Lei Gao (著者), Jinfeng Lou (著者), Min Wu (著者), Hong Chen (著者), Lizhi Yang (著者), Jingrui Liu (著者), Xiaoxue Zhu (著者), Xiaojiao Li (著者), Cuiyun Li (著者), Meng Wang (著者), Chengjiao Liu (著者), Weibo Guo (著者), Yuan Wang (著者), Zhongqiang Gao (著者), Lei Han (著者), Daidi Wang (著者), Weili Jin (著者), Yanhua Ding (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Objective: Hepenofovir, a novel hepatic targeting prodrug of tenofovir, has been developed for the treatment of chronic hepatitis B (CHB). This is a first-in-human study to evaluate the pharmacokinetics (PK) and tolerability of single and multiple escalating doses of hepenofovir in healthy Chinese s...